Search Results for: covid-19
Articles
SPECIAL FEATURE - PFS & Parenteral Manufacturing: How COVID-19 Changed the Market May 3, 2021
Contributor Cindy Dubin explores how device developers and parenteral contract development and manufacturing organizations (CDMOs) are addressing current challenges, as well as advancements in customized device design, the continuous effort to incorporate safety and human factors, and how COVID-19 is shaping the future of the market.
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-Based COVID-19 Vaccine Candidate April 21, 2021
The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. recently announced initiation of a rolling submission for CVnCoV, the company’s mRNA-based COVID-19 vaccine….
Akston Biosciences Launches Phase 1/2 Clinical Trial of Second-Generation COVID-19 Vaccine April 14, 2021
Akston Biosciences Corporation recently announced the first participants have been dosed in an open-label trial of AKS-452, its COVID-19 vaccine...AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections April 8, 2021
AzurRx BioPharma, Inc. recently announced it has initiated its Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of...AIM ImmunoTech Posts New Developments in Intranasal COVID-19 Treatment Clinical Study April 8, 2021
AIM ImmunoTech Inc. recently announced it has completed dosing of Cohort 1 in a Phase 1 clinical study on the...Moderna & Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine & Clinical Portfolio April 8, 2021
Moderna, Inc. and Catalent, Inc. recently announced the expansion of their strategic collaboration to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine and potentially other….
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents April 1, 2021
Pfizer Inc. and BioNTech SE recently announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2….
Clinical Trial Data on the Use of Probiotics in Outpatients With COVID-19 March 26, 2021
Researchers at the Hospital General Manuel Gea González in Mexico City have reported results from a study designed to assess the impact of four specific strains of probiotics on the rate of remission from infection with SARS-CoV-2….
CureVac’s COVID-19 Vaccine Candidate Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant in Preclinical Challenge Study March 25, 2021
CureVac N.V. recently announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections...AstraZeneca’s & J&J’s COVID-19 Vaccines Manufacturing Face Viral Vector Shortages March 25, 2021
The latest wave of COVID-19 vaccines - those from AstraZeneca and Johnson & Johnson (J&J) - are recombinant vector vaccines,...Catalent Expands Partnership With Johnson & Johnson to Significantly Increase Capacity for Sterile Manufacturing & Packaging of COVID-19 Vaccine in Italy March 17, 2021
Catalent recently announced an expanded partnership with Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent Biologics will significantly….
Baxter BioPharma Solutions & Moderna Announce Manufacturing Agreement for Covid-19 Vaccine in the US March 10, 2021
Baxter International Inc. and Moderna, Inc. recently announced they have entered into an agreement for Baxter BioPharma Solutions to provide fill/finish sterile manufacturing services and….
Mateon Provides Update on Global Covid-19 Study March 10, 2021
Mateon Therapeutics, Inc. recently announced it has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients,...Ridgeback Biotherapeutics & Merck Announce Preliminary Findings From Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir March 8, 2021
Merck and Ridgeback Biotherapeutics recently announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA….
Enzo Announces its Molecular Test Detects Current COVID-19 Variants March 4, 2021
Enzo Biochem, Inc. recently announced results of an analysis showing that tests processed on the company’s proprietary GENFLEX molecular diagnostic...AMRI Joins Network of Approved Manufacturers of Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine February 25, 2021
Albany Molecular Research, Inc. recently announced that the company has been chosen to support the development and manufacture of lipid excipients...Altimmune Announces FDA Clearance of Single-Dose, Needle-Free, Intranasal COVID-19 Vaccine Candidate February 17, 2021
Altimmune, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID….
Synairgen Announces Dosing Has Commenced With Its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients February 17, 2021
Synairgen plc recently announced that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase...GSK & CureVac to Develop Next-Generation mRNA COVID-19 Vaccines February 4, 2021
GlaxoSmithKline plc and CureVac N.V. recently announced a new €150-million collaboration, building on their existing relationship, to jointly develop next-generation...Cerba Research Announces Time-Saving COVID-19 Exploratory Tools & NGS Advancements January 28, 2021
Cerba Research recently announced it has developed two new COVID-19 exploratory tools to enhance clinical research for the development of vaccines and treatments for COVID-19 and other infectious diseases…..
